Christopher McCann
Overview
Explore the profile of Christopher McCann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moss D, McCann C, Kerr E
Sci Signal
. 2022 Oct;
15(756):eabj3490.
PMID: 36256706
Mutations in guanosine triphosphatase KRAS are common in lung, colorectal, and pancreatic cancers. The constitutive activity of mutant KRAS and its downstream signaling pathways induces metabolic rewiring in tumor cells...
2.
Grinkevitch V, Wappett M, Crawford N, Price S, Lees A, McCann C, et al.
Mol Cancer Ther
. 2022 Jan;
21(4):594-606.
PMID: 35086954
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these...
3.
Crawford N, Stott K, Sessler T, McCann C, Mcdaid W, Lees A, et al.
Mol Cancer Ther
. 2021 Aug;
20(9):1627-1639.
PMID: 34389694
Inhibitors of apoptosis proteins (IAPs) are intracellular proteins, with important roles in regulating cell death, inflammation, and immunity. Here, we examined the clinical and therapeutic relevance of IAPs in colorectal...
4.
McCann C, Kerr E
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34283054
Drug resistance is a major cause of cancer treatment failure, effectively driven by processes that promote escape from therapy-induced cell death. The mechanisms driving evasion of apoptosis have been widely...
5.
McCann C, Matveeva A, McAllister K, Van Schaeybroeck S, Sessler T, Fichtner M, et al.
FEBS J
. 2021 Mar;
288(18):5374-5388.
PMID: 33660894
Resistance to chemotherapy-induced cell death is a major barrier to effective treatment of solid tumours such as colorectal cancer, CRC. Herein, we present a study aimed at developing a proteomics-based...
6.
Fichtner M, Bozkurt E, Salvucci M, McCann C, McAllister K, Halang L, et al.
Cell Death Dis
. 2020 Dec;
11(11):1020.
PMID: 33257690
Colorectal cancer is a molecularly heterogeneous disease. Responses to genotoxic chemotherapy in the adjuvant or palliative setting vary greatly between patients, and colorectal cancer cells often resist chemotherapy by evading...
7.
Lees A, McIntyre A, Crawford N, Falcone F, McCann C, Holohan C, et al.
Proc Natl Acad Sci U S A
. 2020 Jul;
117(30):17808-17819.
PMID: 32661168
p53 is the most frequently mutated, well-studied tumor-suppressor gene, yet the molecular basis of the switch from p53-induced cell-cycle arrest to apoptosis remains poorly understood. Using a combination of transcriptomics...
8.
Humphreys L, Fox J, Higgins C, Majkut J, Sessler T, McLaughlin K, et al.
EMBO Rep
. 2020 Feb;
21(3):e49254.
PMID: 32009295
The long FLIP splice form FLIP(L) can act as both an inhibitor and promoter of caspase-8 at death-inducing signalling complexes (DISCs) formed by death receptors such as TRAIL-R2 and related...
9.
Matveeva A, Fichtner M, McAllister K, McCann C, Sturrock M, Longley D, et al.
PLoS Comput Biol
. 2019 Sep;
15(9):e1007374.
PMID: 31553717
Ligand binding to death receptors activates apoptosis in cancer cells. Stimulation of death receptors results in the formation of intracellular multiprotein platforms that either activate the apoptotic initiator Caspase-8 to...
10.
Reed M, McGrath M, Black P, Lewis S, McCann C, Whiting S, et al.
Diagn Progn Res
. 2019 May;
2:18.
PMID: 31093566
Background: In recent years, there has been increasing focus on the earlier detection of deterioration in the clinical condition of hospital patients with the aim of instigating earlier treatment to...